Arenaviridae infectious disease
MONDO:0005650Virus diseases caused by the arenaviridae.
Also known as: Arenaviridae caused disease or disorder, Arenaviridae disease or disorder, arenavirus infectious disease, disease due to arenavirus, Arenaviridae infection, arenavirus infection, arenavirus infections, disease caused by arenavirus
11 clinical trials for this condition and its sub-types, 1 tagged with Arenaviridae infectious disease itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Arenaviridae infectious disease
-
Lassa virus infectious disease 1 trial · 6 incl. sub-types
1 sub-type
- Lassa fever 6 trials
-
Arenavirus hemorrhagic fever 0 trials · 6 incl. sub-types
2 sub-types
- Lassa fever 6 trials
- Argentine hemorrhagic fever 0 trials
-
Lymphocytic choriomeningitis 1 trial
-
New vaccine could stop deadly lassa fever
Vaccine OngoingThis early-stage trial is testing a new vaccine called LASSARAB, designed to protect against Lassa fever, a serious viral illness. The vaccine uses a modified rabies virus to deliver the Lassa antigen and includes an adjuvant to boost the immune response. 55 healthy adults will r…
Phase 1 • Sponsor: Wilbur Chen, MD, MS • Aim: Vaccine
Last updated Jun 27, 2026 13:00 UTC
-
Experimental IV drug targets deadly fevers in military personnel
Disease control PausedThis trial investigates whether intravenous ribavirin can help treat people with Crimean-Congo hemorrhagic fever or Lassa fever, two severe viral infections. The study enrolls up to 30 military-affiliated adults who have a probable or suspected case. Participants receive a specif…
Sponsor: U.S. Army Medical Research and Development Command • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New oral drug shows promise against deadly lassa fever in west africa trial
Disease control PausedThis study tests a new oral antiviral drug, ARN-75039, for treating Lassa fever, a serious viral illness common in West Africa. About 135 hospitalized adults will receive either a high or low dose of the new drug or the standard IV treatment, ribavirin, for 10 days. The goal is t…
Phase 2 • Sponsor: Arisan Therapeutics, Inc. • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Scientists compare immune responses to viral and bacterial infections in ICU patients
Knowledge-focused OngoingThis study looks at how the immune system of patients in the intensive care unit (ICU) responds to severe infections caused by viruses or bacteria. Researchers will take extra blood samples from 38 adults to analyze immature granulocytes, a type of immune cell. The goal is to see…
Sponsor: University Hospital, Limoges • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Simple test may uncover hidden tick-borne brain infections
Knowledge-focused By invitation onlyThis study reviews medical records of 200 people hospitalized with unexplained meningitis or meningoencephalitis. Researchers want to see if adding a test for tick-borne encephalitis (TBE) helps find more cases. No new drug or treatment is being tested—only the impact of a change…
Sponsor: Central Hospital, Nancy, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC